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Abstract
Unverricht-Lundborg type progressive myoclonus epilepsy (EPM1, OMIM 254800) is an autosomal recessive disorder
characterized by onset at the age of 6 to 16 years, incapacitating stimulus-sensitive myoclonus and tonic-clonic epileptic
seizures. It is caused by mutations in the gene encoding cystatin B. Previously, widespread white matter changes and
atrophy has been detected both in adult EPM1 patients and in 6-month-old cystatin B–deficient mice, a mouse model for
the EPM1 disease. In order to elucidate the spatiotemporal dynamics of the brain atrophy and white matter changes in
EPM1, we conducted longitudinal in vivo magnetic resonance imaging and ex vivo diffusion tensor imaging accompanied
with tract-based spatial statistics analysis to compare volumetric changes and fractional anisotropy in the brains of 1 to 6
months of age cystatin B–deficient and control mice. The results reveal progressive but non-uniform volume loss of the
cystatin B–deficient mouse brains, indicating that different neuronal populations possess distinct sensitivity to the damage
caused by cystatin B deficiency. The diffusion tensor imaging data reveal early and progressive white matter alterations in
cystatin B–deficient mice affecting all major tracts. The results also indicate that the white matter damage in the cystatin B–
deficient brain is most likely secondary to glial activation and neurodegenerative events rather than a primary result of CSTB
deficiency. The data also show that diffusion tensor imaging combined with TBSS analysis provides a feasible approach not
only to follow white matter damage in neurodegenerative mouse models but also to detect fractional anisotropy changes
related to normal white matter maturation and reorganisation.
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Introduction
Unverricht-Lundborg disease, also known as a progressive
myoclonus epilepsy type 1 (EPM1, OMIM 254800), is an
autosomal recessive neurodegenerative disorder and the most
common cause of progressive myoclonus epilepsy. EPM1 is
characterized by onset at age of 6–16 years and the symptoms
include stimulus-sensitive myoclonus, tonic-clonic epileptic sei-
zures and ataxia [1]. EPM1 is most commonly caused by a
homozygous dodecamer repeat expansion mutation in the
promoter region of the cystatin B (CSTB) gene, although thirteen
other disease-causing mutations in CSTB are currently known [2–
5]. The causative mutations lead to reduced expression of the
cystatin B (CSTB) protein [6,7] that is a ubiquitously expressed
inhibitor of lysosomal cysteine cathepsins B, H, K, L, and S.
Despite the fact that the causative gene mutations for EPM1 are
known, the underlying mechanisms leading to the characteristic
symptoms of the disease remain elusive. Although EPM1 patients
do not show major cognitive decline, histopathological and
imaging studies have confirmed atrophic changes on several brain
regions of adult EPM1 patients, affecting both grey matter (GM)
and white matter (WM) [1,8,9].
A mouse model for EPM1 has been generated with a targeted
disruption of the mouse Cstb gene (the Cstb-/- mouse) and it
recapitulates the key symptoms of EPM1, including myoclonic
seizures and progressive ataxia [10]. The findings in adult Cstb-/-
mice are compatible with the neuropathology found in patients,
and exhibit neuronal death in the cerebrum and cerebellum,
degenerative changes in the WM, and loss in brain volume [9–13].
In order to clarify the spatiotemporal progression of the brain
pathology, this study aims to quantify the dynamics of brain
atrophy and WM changes in Cstb-/- mice from 1 month of age up
to the fully symptomatic age of 6 months using in vivo magnetic
resonance imaging (MRI) for detecting volumetric changes and ex
vivo diffusion tensor imaging (DTI) with tract-based spatial statistics
(TBSS) analysis for detecting changes in WM integrity [14].
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Materials and Methods
2.1 Ethics statement
All the animal research protocols were approved by the Animal
Ethics Committee of the State Provincial Office of Southern
Finland (decisions ESLH-2005-00507/Ym-23, ESLH-2007-
05788/Ym-23, ESAVI-2010-07744/Ym-23).
2.2 Mice
Cstb-/- mice (129-Cstbtm1Rm/SvJ; stock no. 003486; Jackson
Laboratories) between 1 to 6 months of age were used in the study
and wild-type animals of the same background served as controls.
Animals were maintained under a 12-h light/12-h dark cycle with
lights on at 07:00 a.m., temperature 2261uC, air humidity 50–
60%, and with free access to food and water.
2.3 Magnetic resonance imaging
In vivo MRI was performed on Cstb-/- and control mice (Cstb-/-;
n = 4, all females/controls; n = 4, all females) at 1, 2, 4, and 6
months of age. Mice were anesthetized with 1% isoflurane in 70%
N2O/30% O2, and the body temperature was maintained at 37uC
during imaging. MRI was performed using a 4.7 T Varian
UNITY INOVA MRI system (Varian Inc., Palo Alto, USA) with
an actively decoupled volume coil-quadrature surface coil pair
(Rapid Biomedical GmbH, Rimpar, Germany). A multi-slice (17
slices) spin echo sequence was used to acquire anatomical images
for volumetric analysis with the following parameters;
1006100 mm in-plane resolution; matrix 2566256, slice thickness
0.75 mm, echo time (TE) 40 ms, repetition time (TR) 1.8 s.
Regions of interest (ROIs) were drawn on blinded data sets
according to Paxinos mouse brain atlas [15] for the whole brain
(excluding the medulla), the cerebellum, cerebral cortices, striatum
and hippocampus for each time point using in-house built software
Aedes 1.0 (aedes.uef.fi). For statistical comparisons, we performed
one-way ANOVA with Bonferroni post hoc correction using
GraphPad (Prism 5.0c; GraphPad Software, La Jolla, USA) and
considered p,0.05 as significant.
2.4 Diffusion tensor imaging
For the ex vivo brain DTI, mice that were 2 months old (9 Cstb-/-;
6 female/7 controls; 4 female), 4 months old (9 Cstb-/-; 5 female/6
controls; 2 female) and 6 months old (9 Cstb-/-; 8 female/4
controls; all female) were used.
A TBSS analysis of the FA in 6-month-old Cstb-/- and control
groups (without hemisphere mirroring) has been previously
published together with TBSS data from EPM1 patients [9]. As
the observed changes were bilateral, hemisphere-mirrored FA-
maps were used in the current analysis as described previously
[16]. The previously measured data from 6-month-old animals [9]
were re-analysed using hemisphere mirroring and included as the
final time point in this study.
The ex vivo DTI was performed as previously described [9].
Briefly, 4% paraformaldehyde fixed brains were immersed in
perfluoroether (Fomblin, Solvay Solexis, Milan, Italy) and DTI
was performed in a 9.4 T vertical magnet (Oxford Instruments,
Abingdon, UK) interfaced to a Varian DirectDrive console
(Varian Inc., Palo Alto, USA). Data acquisition was done using
a 3D fast spin echo sequence (TR = 1000 ms; TE = 28 ms; echo
train length = 2, data matrix 128664664, zero padded to
25661286128; FOV 20610610 mm3). Six 3D data sets with
diffusion weighting (diffusion time 17 ms, b-value 1000 s/mm2) in
six non-collinear directions and one data set without diffusion
weighting were acquired. The measurement time was 16 hours.
2.5 Tract-Based Spatial Statistics
For TBSS analysis we utilized the TBSS protocol for FA [14]
modified for use in rodents [16]. The TBSS analysis of FA-values
comparing Cstb-/- mice with controls was performed for all time
points (2, 4 and 6 months). In order to present all TBSS results in a
common 3D space, thus making comparison of affected WM-
tracts easier, all 44 animals were also registered into a single best
registration target. In brief, the diffusion tensor model for each
brain was calculated and resulting individual FA maps were used
in subsequent co-registration and TBSS procedures. To be able to
co-register all animals in the study to a common 3D space, a free-
search for the most representative brain, and thus the best
registration target in the whole data set, was applied. This was
done in order to minimize the image warping required for each
brain volume. The calculated best target was subsequently used in
TBSS-scripts as a template into which final transformations were
targeted to. After target selection, direct non-linear co-registration
of individual FA maps was then applied to this common template
brain. Hemisphere mirrored FA-maps were included in the
analysis and treated as repeated measurements [16]. We also
assessed whether changes in axial (AD, diffusion along the axonal
tract) or radial (RD, radial diffusion perpendicular to axons)
diffusivity were responsible for the FA changes. AD and RD
parameters were brought to the same 3D space using the co-
registration warp-fields and tract projection information obtained
during FA TBSS processing. Finally, the results of the TBSS
analysis with p,0.05 (Threshold-Free Cluster Enhancement with
multiple comparison correction) were deemed significant. FA
values in selected anatomical areas were extracted by manually
determining the ROI along the FA-skeleton. Significant FA TBSS
findings and mouse brain atlas [15] were used for navigation. The
extracted values of the Cstb-/- group were compared to those of the
control group. For statistical comparisons, we performed one-way
ANOVA with Bonferroni post hoc correction using GraphPad
(Prism 5.0c; GraphPad Software, La Jolla, USA) and considered
p,0.05 as significant.
Results
3.1 MRI volumetry in Cstb-/- and control mice
Using in vivo MRI volumetry, we measured volumes of the
whole brain, cerebellum, cortex, striatum and hypothalamus at 1,
2, 4, and 6 months of age in individual animals. The whole brain
volume, quantified excluding the medulla, was significantly smaller
in Cstb-/- mice compared to controls already at 1 month, and brain
atrophy was extensive in the 6-month-old animals (Fig. 1 A). While
the whole brain volume in controls continued to increase until 4
months, it decreased in Cstb-/- mice from 2 months onwards (Fig. 1
A). At one month, there was no difference in cerebellar volume
between controls and Cstb-/- mice (Fig. 1 B). The cerebellar
volume in control mice increased until 2 months of age, whereas in
Cstb-/- mice, the cerebellar volume progressively decreased from 1
month until 6 months of age and showed a statistically significant
difference from 2 months onwards. Progress of the volume loss in
the cerebral cortex (Fig. 1 C) was similar to that in the cerebellum,
with Cstb-/- mice showing a significant decrease from 2 months
onwards. The striatum and the hippocampus (Fig. 1 D and E)
showed significant reductions in volume later, at 6 months of age.
It is worth noting that the difference in volume between the groups
was accentuated over the study period as the brain volume in the
control group continued to grow, whilst in the Cstb-/- group, the
brain volume decreased from 1 month onwards.
Degenerative Changes in Cstb-Deficient Mouse Brain
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Figure 1. In vivo MRI-volumetry of Cstb-/- mice revealed early and severe brain atrophy. In vivo MRI-volumetry of Cstb-/- mice from 1 to 6
months showed differences in the volumes of A) the whole brain (excluding the medulla), B) cerebellum, C) cerebral cortex, D) striatum and E)
hippocampus. Time points showing a significant difference in volume are marked with asterisks (statistical comparison was done using one-way
ANOVA with post hoc correction and with p,0.05 considered significant; *, p,0.05; **, p,0.01; ***, p,0.001; ****, p,0.0001).
doi:10.1371/journal.pone.0090709.g001
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3.2 TBSS comparison of DTI data between Cstb-/- and
control mice
TBSS analysis of the DTI data revealed a statistically significant
decrease in FA in several brain regions in Cstb-/- mice compared to
the controls at 2 months (Fig. 2 A; blue color). These regions
include the cerebellum, cerebral cortex, external/internal capsule,
hippocampus, hypothalamus, and thalamus, with the most
dramatic changes in the cerebellum and the thalamus. At 4
months (Fig. 2 A; yellow color), more widespread decrease in FA
within the cerebellum, cerebral cortex, external/internal capsule,
hippocampus, hypothalamus, and the thalamus was detected. At
this time point, TBSS also revealed decreased FA in many brain
regions not affected at 2 months, including the corpus callosum,
medulla, and the striatum. Finally, at 6 months (Fig. 2 A; red color)
the decrease in FA was seen in larger areas within the previously
affected regions, most notably in the corpus callosum, hypothal-
amus, thalamus, and cerebellum. However, at 6 months of age,
only minor changes were detected in the hippocampus. The TBSS
analysis detected significantly elevated RD in the thalamus and the
cerebellum of the Cstb-/- group at 4 months and in the cerebellum
at 6 months (data not shown). TBSS analysis of AD did not reveal
significant differences in any time-point.
3.3 TBSS analysis of DTI data within Cstb-/- mouse and
control groups
The data also showed that FA in the WM changed as the
animals aged and the WM matured (Fig. 2 B, Table 1). TBSS
analysis in the control group showed that the FA-values in most
WM tracts at 2 months were significantly lower when compared to
values at 6 months (Fig. 2 B; FA change in the control group from
2 to 6 months in pink color, bottom layer), demonstrating FA
increase in the WM as a normal phenomena in aging animals.
Similar changes in FA values were also observed in the Cstb-/-
group (Fig. 2 B; FA change from 2 to 6 months in the Cstb-/- group
in green color, top layer), although significant FA changes were
detected in fewer brain regions. Also, in some brain regions such as
the hypothalamus, thalamus and cerebellum, changes were
detected only in restricted sub-regions.
Discussion
Previous imaging studies of EPM1 patients have demonstrated
atrophic changes in GM and WM in several brain regions, most
notably in the cortices and the thalamus [8,9,17–20]. The diversity
in anti-epileptic drug treatments, as well as the heterogeneity of the
studied patient groups in terms of age, gender and disease duration
have made interpretation of the patient data difficult and thus the
existing reports offer only a limited view of EPM1 pathology.
Longitudinal imaging studies in human patients are not usually
feasible as they are expensive to perform and in a disease like
EPM1, could span decades. Thus, the progression of pathological
changes in EPM1 has remained unclear. Since previous studies
have implicated that the Cstb-/- mouse is a good model for EPM1
in terms of clinical features [10], and brain pathology [9,13], it
provides a mean to monitor the spatiotemporal progression of
brain pathology with implications to disease course in human
patients as well.
Here we performed a study in Cstb-/- mice utilizing DTI
accompanied by TBSS analysis and longitudinal MRI volumetry
to investigate the spatiotemporal pattern of atrophy and WM
damage from early symptomatic (1 month of age) to fully
symptomatic (6 months of age) mice. The time points were
selected based on our previous histological data [13] and
manifestation of disease symptoms in mice [10]: at 1 month of
age the mice show glial activation, neuron loss in the cerebral
cortex and the first signs of myoclonia, and at 6 months of age the
mice usually demonstrate ataxia accompanied by widespread
gliosis and neuron loss in the brain (Fig. 3). Our results show that
in the Cstb-/- mouse brain also the WM is affected early in disease
pathogenesis and is progressively damaged, eventually affecting all
major WM tracts. The brain atrophy and WM damage manifest
with varying degree and timing in different brain regions, the
cerebellum and the thalamus being among the most vulnerable
regions. Importantly, our study demonstrates that a multi-time-
point study of DTI changes combined with TBSS analysis is a
feasible approach both for investigating progressive WM damage
in neurodegenerative mouse models and for detecting FA changes
related to normal WM maturation and reorganisation.
Cerebellar [18], thalamic and cortical atrophy [8] has been
reported in EPM1, and the whole brain volume in adult EPM1
patients has been shown to be 10% smaller compared to healthy
controls [8]. In agreement, limited histopathological data on
EPM1 patients have shown loss of cerebellar granule and Purkinje
cells as well as neuronal degeneration and loss in the cerebral
cortex, striatum, thalamus and brain stem [1,21–23]. Although the
progressive nature of atrophy in EPM1 patients has been difficult
to demonstrate, the severity of myoclonia has been shown to be
associated with cortical thinning [8]. The histopathological
findings in the Cstb-/- mice are very similar to those in EPM1
patients, although atrophy is more drastic in the mouse brain [13].
Studies from young adult Cstb-/- mice have shown volume loss and
selective loss of neurons within the cerebellum and cerebral cortex
and the relative sparing of the hippocampus [10,12,13,24].
Alterations in GABAergic signalling have also been demonstrated
both in young and aged animals [25,26]. Our volumetric data are
concordant with these findings as the MRI data in the Cstb-/-
mouse brain show that the volume loss, which is widespread
already at the early stages of disease, is not spatially uniform and is
progressive with only limited WM damage and late atrophy in the
hippocampus. Moreover, the data show that in Cstb-/- mice the
brain volume never reaches that in the control mice. Even though
we did not detect statistically significant atrophy of individual
brain regions in one month-old animals, the total brain volume
was significantly smaller already at this point. Therefore, it is
possible that disturbed developmental processes precede neurode-
generation in Cstb-/- mouse brain [10,12,13].
We have previously shown that WM damage in 6-month old
Cstb-/- mice reflects local axonal degeneration [9]. The sequence
and timing of pathological changes in the Cstb-/- mouse brain
imply that the WM damage is most likely secondary to the early-
onset non-uniform microglial activation that precedes astrocytic
activation, neuron loss and the appearance of myoclonus [13].
Activation of microglia and secretion of proinflammatory
cytokines are known to contribute to many neurodegenerative
disorders, including Alzheimer’s disease, Parkinson’s disease,
amyotrophic lateral sclerosis and Huntington’s disease [27].
Moreover, microglia-derived cathepsin B, a target protein of
CSTB, has been shown to have a role in WM damage in a mouse
model of multiple sclerosis [28]. Cathepsin B levels are increased
in both Cstb-/- mice and EPM1 patient cells [29,30] and mice
deficient for both CSTB and cathepsin B show significantly less
cerebellar apoptosis [31]. Thus, it is possible that elevated
cathepsin B activity due to reduced inhibition by CSTB
contributes to axonal degeneration and subsequent WM loss also
in Cstb-/- mice.
The Cstb-/- mice showed a decrease in FA on several brain
regions already at 2 months of age with the changes accentuating
as the animals aged. This finding suggests that in the future,
Degenerative Changes in Cstb-Deficient Mouse Brain
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Figure 2. TBSS analysis of DTI data showed WM-changes emerging at the thalamus and cerebellum. A) The TBSS comparison of FA
between Cstb-/- mice and controls shown in three orientations: sagittal (left), coronal (middle) and horizontal (right). Areas of significant (p,0.05,
multiple comparison corrected, with threshold-free cluster enhancement) FA decrease are shown in blue at 2 months of age (first row), yellow at 4
months of age (second row) and red at 6 months of age (third row), and a composite image overlaying all timepoints (fourth row). B) Longitudinal
TBSS analysis of the FA between 2 months and 6 months of age show areas of significantly lower FA at 2 months compared to 6 months of age. The
green color represents areas of significant FA change in Cstb-/- mice and pink shows control mice, with the Cstb-/- group results on top. Results are
shown layered on top of the mean FA map calculated from all brains in the study. The FA changes are shown in three orientations: sagittal (top),
coronal (middle) and horizontal (bottom).
doi:10.1371/journal.pone.0090709.g002
Degenerative Changes in Cstb-Deficient Mouse Brain
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longitudinal DTI combined with TBSS could be a feasible
approach for monitoring progressive damage of the WM in mouse
models. Decreased FA in Cstb-/- mice presumably is a consequence
of axonal degeneration, since loss of axons results in higher
extracellular volume in the WM, which increases radial diffusion
of water parallel to tracts. This is reflected as increased RD in
DTI, which became evident in the 4-months -old Cstb-/- mice in
our study. As TBSS analysis of axial diffusion did not reveal
significant differences at any time-point, it is probable that an
increase in radial diffusion contributes more to the detected
decrease in FA than the changes in axial diffusion.
The WM matures as the animals age and in healthy mice,
increasing fibre tract coherence and compaction in the WM can
be detected as a FA increase. The increase in FA has been shown
to continue well beyond 2 months of age [32–34]. In agreement
with these previous results, our TBSS analysis of DTI data in the
control mouse group showed increased FA values in most major
WM tracts from 2 to 6 months of age. The data thus demonstrate
that TBSS could also be utilized to monitor maturation of healthy
WM. In the Cstb-/- mice, a less pronounced FA increase over time
was observed in the most seriously damaged regions, e.g. cerebral
cortex, cerebellum and thalamus, probably illustrating the
concurrent degenerative changes.
EPM1 is characterized by stimulus-sensitive myoclonus, tonic-
clonic seizures and ataxia. While epileptic seizures in EPM1 can
be well controlled with drugs, myoclonus is in most cases highly
incapacitating and remains resistant to therapy. The myoclonus is
often the manifesting symptom in EPM1 patients and becomes
progressively more debilitating over the next 5 to 10 years followed
by stabilization [35], the reason for which is unknown. EPM1
patients share clinical characteristics with subcortical movement
disorders that manifest as ataxia and myoclonus from subcortical
structures. Previous studies have shown altered inhibition in the
motor cortices and the thalamocortical system of the patients [36–
38] and a thalamocortical dopaminergic defect in EPM1 has also
been reported [39]. In addition, we recently reported widespread
WM damage in EPM1 patients [9]. Concordantly, previous [9,13]
and current results from mice show subcortical structures involved
in movement control (e.g. striatum and thalamus) severely
affected. The present data from Cstb-/- mouse also confirms that
the pathological changes in the WM are widespread and that the
changes manifest early, are progressive and show regional
Table 1. ROI based quantification of FA values in different anatomical locations in Cstb-/- and control mice.
FA 2 Months FA 4 Months FA 6 Months
Cstb-/-/control Cstb-/-/control Cstb-/-/control
Amygdala 0.2560.01/0.2760.01 0.2660.01/0.2860.01 0.29±0.01/0.32±0.01
Brainstem 0.4160.01/0.4360.01 0.4260.01/0.4560.01 0.46±0.01/0.51±0.02
Cerebellar peduncle 0.4860.01/0.4860.01 0.5360.02/0.5260.01 0.5360.02/0.5460.01
Cerebellum 0.47±0.01/0.55±0.03 0.46±0.01/0.62±0.01 0.46±0.03/0.59±0.04
Corpus callosum 0.5460.03/0.5660.06 0.5260.02/0.6360.05 0.56±0.03/0.74±0.04
Cortex 0.24±0.01/0.30±0.02 0.22±0.01/0.31±0.02 0.24±0.01/0.29±0.01
External capsule 0.3760.01/0.3660.01 0.36±0.01/0.41±0.01 0.34±0.01/0.43±0.01
Hippocampus 0.3960.01/0.4260.02 0.3960.01/0.4360.01 0.45±0.02/0.53±0.01
Hypothalamus 0.3060.01/0.3360.02 0.3460.01/0.3560.02 0.31±0.01/0.40±0.02
Internal capsule 0.6360.01/0.6660.01 0.61±0.01/0.68±0.01 0.58±0.01/0.64±0.02
Striatum 0.2760.01/0.2760.01 0.2460.01/0.2860.02 0.2060.01/0.2360.03
Thalamus 0.36±0.02/0.43±0.02 0.37±0.01/0.44±0.01 0.44±0.01/0.54±0.03
Values have been averaged from hemisphere-mirrored FA-skeletons. Brain regions showing significant (statistical comparison was done using one-way ANOVA with
Bonferroni post hoc correction and with p,0.05 considered significant) differences in FA values are in bold. All values are shown with the standard error of mean (SEM).
doi:10.1371/journal.pone.0090709.t001
Figure 3. Sequence of pathological events in Cstb-/- mice. The figure summarises the sequence of the pathological events in the Cstb-/- mice as
detected in the current study. Emergence of key symptoms and previous findings reported by Pennacchio et al. (1998) and Tegelberg et al. (2012)
have also been included in the figure.
doi:10.1371/journal.pone.0090709.g003
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specificity. Based on the extent and temporal pattern of pathologic
changes in the cerebral cortex, thalamus and cerebellum in EPM1
patients and Cstb-/- mice [9,13] it is likely that atrophy and WM
damage in the thalamocortical system and the cerebellum both
contribute to the motor disturbances in EPM1 and explain their
resistance to treatment.
Conclusions
The brain pathology of Cstb-/- mice is characterized by early-
onset and progressive degeneration affecting all major WM tracts,
which likely occurs secondary to glial activation and neuronal
death and probably augments the myoclonic seizures and ataxia.
A multi-timepoint study of DTI changes with TBSS analysis
provides a feasible approach to follow both normal WM
development and reorganisation and progressive WM damage in
mouse brain.
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